Welcome to AVID-CC trial website!
Full study title: Adalimumab in COVID-19 to prevent respiratory failure in community care.
PURPOSE OF THE TRIAL
COVID-19 is caused by a virus called SARS-CoV-2. Most (8 out of 10) people with the disease have only mild symptoms, but in some people the condition can be severe and even fatal. Patients who develop severe disease tend to have a lot of inflammation – a process in which the immune system goes into overdrive and may cause damage as well as fighting the virus.
We have been funded by the Wellcome Trust to investigate whether a treatment called anti-TNF (which has been in use for many years for inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and Crohn's disease) can reduce inflammation in COVID-19 and therefore reduce the progression of COVID-19 to more severe disease, in people in community care. People who are residents of community care facilities have been particularly hard hit by COVID-19 and so we are conducting the study to see if the treatment works in this group. A company called Sandoz will be providing the medication (Adalimumab) for the trial.
Please note the AVID-CC trial has now closed.
AVID-CC will be delivered by hospital at home teams - this is a relatively new model of care in which hospital based teams reach out into the community to deliver care with the specific intent of avoiding admission to hospital.
We are hoping to enrol up to 750 men and women aged 18 or over who are in community care across the UK to take part in our AVID-CC trial.
To find out what would be involved if you chose to take part, including the potential benefits and risks, click here.
Adalimumab is an antibody drug which works against a chemical signalling molecule called Tumour Necrosis Factor. Tumour Necrosis Factor (TNF) switches on the body’s immune system to fight infections.
In some inflammatory diseases such as rheumatoid arthritis there is too much TNF and blocking it helps control the disease.
There is evidence that TNF is raised in COVID-19 so in the AVID-CC trial we are investigating whether blocking TNF is helpful in COVID-19. In this trial, Adalimumab will be given by injection under the skin (subcutaneous).
Monday 1st June 2021
Please note the AVID-CC trial has now closed.
Monday 26th April 2021
Please note that recruitment to AVID-CC has temporarily been paused, check back here for future updates!
Monday 15th February 2021
AVID-CC is officially open for recruitment!
Our first site open to recruitment is Oxford University Hospitals NHS Foundation Trust and we have another three currently in set-up.
